Tunisian Clinical Registry on Hypoparathyroidism and Pseudo-hypoparathyroidism

计划入组 1,000 人 · 首次发布于 2024 年 6 月 6 日

Hypoparathyroidism in Denmark

计划入组 1,000 人 · 首次发布于 2011 年 12 月 23 日

Hypoparathyroidism Natural History Study

计划入组 106 人 · 首次发布于 2023 年 3 月 31 日

PTHR1 agonist (hypoparathyroidism)

Parathyroid hormone(Natpara, Natpar)

Palopegteriparatide(Yorvipath)

Ascendis Pharma's Yorvipath Commercially Available in the US, Offering New Hope for Hypoparathyroidism

Palopegteriparatide Shows Sustained 3-Year Benefits in Hypoparathyroidism Treatment

TransCon PTH Shows Sustained 4-Year Efficacy in Hypoparathyroidism Patients